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Abstract
Background: Cytokine mediated induction of the mucosal addressin cell adhesion molecule-
1(MAdCAM-1) expression is associated with the onset and progression of inflammatory bowel
disease (IBD).
Results: Using western blotting and cell-based ELISA, we show in this study that troglitazone, an
activator of the peroxisome proliferator-activated receptor-γ (PPAR-γ) ,  w i d e l y  u s e d  i n  t h e
treatment of diabetes, has as well recently been highlighted as protective in models of inflammation
and cancer. We found that troglitazone (10–40 µM), significantly reduced the TNF-α (1 ng/ml)
mediated induction of endothelial MAdCAM-1 in a dose-dependent manner, achieving a 34.7% to
98.4% reduction in induced MAdCAM-1. Trogliazone (20µM) reduced TNF-α induced VCAM-1,
ICAM-1 and E-selectin expression. Moreover, troglitazone significantly reduced α4β7-integrin
dependent lymphocyte adhesion to TNF-α cultured endothelial cells.
Conclusions: These results suggest that PPAR-γ agonists like troglitazone may be useful in the
clinical treatment of IBD.
Background
Endothelial cell adhesion molecules or 'ECAMs' play
essential roles in the development of chronic inflamma-
tion by recruiting leukocytes, especially lymphocytes
through their ability to promote leukocyte rolling, firm
adhesion and extravasation [15]. Tissue infiltration by
leukocytes is a common hallmark in several chronic
inflammatory states which include the inflammatory
bowel diseases, ulcerative colitis (UC), and Crohn's dis-
ease (CD), but also several other chronic inflammatory
states such as arthritis, lupus, diabetes [17,47,58]. In the
setting of IBD, the expression of ECAMs like ICAM-1,
VCAM-1, and MAdCAM-1 is observed in experimental
models of colitis, [11,33,34,48] and also within the
inflamed human colon in Crohn's disease and ulcerative
colitis [3,49]. Among the adhesion molecules that are up-
regulated in IBD, MAdCAM-1, the mucosal cell adhesion
molecule is thought to be preeminent in the development
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of chronic gut inflammation. MAdCAM-1 is normally
expressed in the gut, and its expression is dramatically
increased during inflammation [11,48]. The functional
significance of increased expression of MAdCAM-1 in IBD
is supported by several reports which demonstrate that
immunoneutralization of either MAdCAM-1 or its lym-
phocyte ligand, the α4β7 integrin, attenuate inflamma-
tion and mucosal damage in a variety of animal models of
colitis [14,24,55]. However, since monoclonal antibodies
directed against other ECAMs, particularly VCAM-1, can
as well reduce disease activity in animal models of colitis
[2,16,46,53], the literature suggests that MAdCAM-1 is
probably necessary, but insufficient for the maximal pen-
etrance of experimental and clinical IBD. Based on these
results, it is apparent that an improved understanding of
the mechanisms regulating ECAM expression, especially
MAdCAM-1, might help to design improved therapies for
colitis.
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily of
transcription factors, whose activities are regulated
through the high affinity binding of small lipophilic lig-
ands that include steroid hormones [29]. A new class of
antidiabetic drugs, known as 'glitazones' which includes
troglitazone, rosiglitazone, and pioglitazone, have been
developed as agonists that bind to the gamma (γ)-subtype
of the PPARs. While glitazones have been extensively used
in the treatment of diabetes, several investigators have
now demonstrated that PPAR-γ ligands will markedly
reduce colonic inflammation of in two different mouse
models of colitis [12,51]. In addition, glitazones provide
some benefit in the treatment of ulcerative colitis in
humans as well [27].
Although PPAR-γ is expressed at high levels in adipose tis-
sues, PPAR-γ has also been described in many other kinds
of cells, including those in the vasculature like endothelial
cells, vascular smooth muscle cells and monocytes and
macrophages [19]. Although it not yet completely clear,
the literature suggests that glitazones may be therapeutic
in these models through the ability of these PPAR-γ acti-
vators to inhibit several events in inflammation particu-
larly leukocyte infiltration into tissues mediated by NF-
kB-dependent ECAM expression [6,21,32,38,51].
However, the literature does not uniformly support pro-
tective roles for all PPARs. For example, it has been sug-
gested that activation of PPAR-α, rather than PPAR-γ
activation is responsible for blocking cytokine induced
ECAM expression [30,41] and these differences may
reflect tissue- and/or species specific responses to glita-
zones. Regardless, glitazones might be therapeutic in the
setting of IBD through their ability to restrict expression of
MAdCAM-1, one of the more important regulators of gut
inflammation in IBD. However, this has not yet been
investigated.
In the present study we have examined the ability of a can-
didate glitazone PPAR-γ ligand, troglitazone, to limit
cytokine induction of MAdCAM-1 and also VCAM-1,
ICAM-1 and E-selectin, and decrease MAdCAM-1 depend-
ent lymphocyte endothelial adhesion in vitro.
Results
PPAR-γ expression by endothelial cells
To confirm the presence of PPAR-γ on SVEC endothelial
cells, western blotting for PPAR-γ was performed using an
antibody generated to a synthetic peptide corresponding
to amino acid residues 284–298 of murine PPAR-γ;
importantly, this antibody exhibits no significant homol-
ogy to PPAR-α. This antibody recognized a PPAR-γ specific
band at 55 kD by western blotting in SVEC cells (Fig. 1).
TNF-α induced MAdCAM-1 protein expression is reduced 
by troglitazone, a PPAR-γ ligand
To examine the effect of PPAR-γ activation on endothelial
cell inflammatory responses, SVEC endothelial cells were
treated with TNF-α either with or without a pre- and co-
treatment with troglitazone. TNF-α (1 ng/ml, 24 h)
increased MAdCAM-1 expression to 13.4 times that of the
untreated control level. This TNF-α induced MAdCAM-1
was dose dependently attenuated by pre- and co-treat-
ment with troglitazone (i.e. from 69% to 7% of TNF-α
stimulated levels) at concentrations of 10 to 40 µM (Fig.
2). At 40 µM troglitazone, the MAdCAM-1 expression (7%
of TNF-α stimulated) was not significantly different from
untreated controls. Troglitazone alone did not alter the
expression of MAdCAM-1 (data not shown). Troglitazone
was not overtly toxic, and did not affect cell protein con-
tent (i.e. protein content per well), or change the expres-
sion of either actin or vimentin, two cell structural
proteins (measured by total protein staining of transferred
western blots) (data not shown).
PPAR-γ expression in SVEC endothelial cell Figure 1
PPAR-γ expression in SVEC endothelial cell. Western 
blotting for PPAR-γ in SVEC cells reveals a 55 kD band after 
reacting with anti-PPAR-γ peptide antibody, indicating that 
PPAR-γ is in fact present within the cells used in this study.BMC Physiology 2005, 5:3 http://www.biomedcentral.com/1472-6793/5/3
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To examine the effect of troglitazone on other ECAMs
expression stimulated by TNF-α surface expression assay
was performed.
TNF-α induced VCAM-1 protein expression is reduced by 
troglitazone, a PPAR-γ ligand
TNF-α (1 ng/ml, 24 h) enhanced VCAM-1 expression to
8.5 times that of untreated controls. This elevated expres-
sion was significantly reduced (to only 80% of the TNF-α
stimulated level) by troglitazone at 20 µM (Fig. 3). Alone,
this compound had no effect on the expression of VCAM-
1 (Fig. 3).
TNF-αinduced ICAM-1 protein expression is reduced by 
troglitazone, a PPAR-γ ligand
TNF-α (1 ng/ml, 24 h) increased ICAM-1 expression to a
level 4.7 times greater than untreated control levels. This
TNF-α enhanced ICAM-1 expression was strongly attenu-
ated (to 32% of the TNF-α stimulated level) by troglita-
zone at 20 µM (Fig. 4). Again, troglitazone alone had no
effect on the expression of ICAM-1 (Fig. 4).
TNF-α induced E-selectin protein expression is reduced by 
troglitazone, a PPAR-γ ligand
TNF-α (1 ng/ml, 24 h) increased the expression of E-selec-
tin 4 times over untreated control levels; this increase in E-
selectin was also blocked by troglitazone (to 22% of the
TNF-α induced MAdCAM-1 protein expression is reduced by troglitazone, a PPAR-γ ligand Figure 2
TNF-α induced MAdCAM-1 protein expression is reduced by troglitazone, a PPAR-γ ligand. TNF-α (1 ng/ml, 24 
h) induced MAdCAM-1 expression was dose dependently blocked by the PPAR-γ ligand, troglitazone at concentrations 
between 10 to 40 µM (Fig. 2).
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TNF-α stimulated level) at 20 µM (Fig. 5). Alone, troglita-
zone had no effect on E-selectin expression (Fig. 5).
Adhesion of α4β7 expressing lymphocytes to TNF-α 
stimulated endothelium
Having established that troglitazone exerts a significantly
protective effect against TNF-α stimulated endothelial
MAdCAM-1 induction, we examined the effects of trogli-
tazone on the adhesion of α4β7 expressing mouse lym-
phocytes (using the cell line TK-1) to endothelial
monolayers following TNF-α treatment. TNF-stimulation
(24 h) significantly increased the adhesion of TK-1 lym-
phocytes to SVEC monolayers. Troglitazone (20 µM) sig-
nificantly reduced TK-1 adhesion in response to TNF-α
stimulation at 24 h (Fig. 6). Troglitazone did not modify
the basal level of lymphocyte adhesion to the endothe-
lium without TNF-α treatment.
TNF-α induced phosphorylation of NF-kB p65 is prevented 
by troglitazone, a PPAR-γ ligand
Mechanistically, the expression of all of these adhesion
molecules is known to depend on the activation of NF-kB
following TNF-α stimulation. Therefore, we examined
whether troglitazone-mediated protection against TNF-α
induced MAdCAM-1 expression and lymphocyte adhe-
sion were related to the activation and/or inhibition of
NF-kB. In this study, phosphorylation of the p65 subunit
of NF-kB was used as an index of NF-kB activation. TNF-α
(1 ng/ml, 1 h) induced the phosphorylation of NF-kB
p65; this activation was significantly reduced by the
TNF-α induced VCAM-1 protein expression is reduced by troglitazone, a PPAR-γ ligand Figure 3
TNF-α induced VCAM-1 protein expression is reduced by troglitazone, a PPAR-γ ligand. TNF-α (1 ng/ml, 24 h) 
induced VCAM-1 expression was also blocked by the PPAR-γ ligand, troglitazone at 20 µM (Fig. 3). Alone, this compound had 
no effect on the expression of VCAM-1 (Fig. 3).
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PPAR-γ ligand, troglitazone at 20 µM (Fig. 7). Alone, tro-
glitazone significantly attenuated the phosphorylation of
NF-kB p65 compared to untreated controls (Fig. 7).
Discussion
MAdCAM-1 is a 60 KD endothelial cell surface molecule
that is strongly expressed by mucosal endothelial cells,
particularly following exposure of these cells to pro-
inflammatory cytokines such as TNF-α. Expression of
MAdCAM-1 has as well been reported in the brain, and in
the heart, [23,47], and based on these findings, it has now
been suggested that MAdCAM-1 might play roles in
chronic inflammation of these organs as well.
With respect to inflammatory bowel disease, MAdCAM-1
appears to be necessary for lymphocyte homing to
mucosa associated lymphoid tissue [3-5,50]. Since MAd-
CAM-1 is normally expressed within the gut microvascu-
lature, and is dramatically increased during IBD, it has
been suggested that increased MAdCAM-1 expression par-
ticipates in the etiology of IBD through its ability to con-
trol homing of lymphocytes to the gut. This notion is
supported by several observations that show that antibod-
ies directed against either MAdCAM-1, or its lymphocyte
ligand, the α4β7 integrin will significantly attenuate
several indices of injury in experimental models of colitis
[24,39].
TNF-α induced ICAM-1 protein expression is reduced by troglitazone, a PPAR-γ ligand Figure 4
TNF-α induced ICAM-1 protein expression is reduced by troglitazone, a PPAR-γ ligand. TNF-α (1 ng/ml, 24 h) 
induced ICAM-1 expression was dose dependently blocked by the PPAR-γ ligand, troglitazone at 20 µM (Fig. 4). Alone, this 
compound had no effect on the expression of ICAM-1 (Fig. 4).
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TNF-α is thought to be perhaps the most important
cytokine responsible for driving the onset and progression
of IBD. Because of this primary role of TNF-α in IBD, anti-
TNF-α antibody therapy has been successfully used in IBD
to reduce both colonic injury and expression of ECAMs in
IBD [1]. While TNF-α significantly increased the expres-
sion of MAdCAM-1, it also increases the expression of
intercellular cell adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule-1 (VCAM-1), E-selectin, P-selectin
[15,37]. It should be noted that in colitis, all of these
adhesion molecules are elevated in the colon [25], and
likely contribute to the development of chronic gut injury.
This is the first study to demonstrate that a PPAR-γ ligand,
troglitazone, can significantly reduce the expression of
MAdCAM-1, an endothelial cell adhesion molecule which
is closely linked to chronic gut inflammation. Troglita-
zone significantly reduced TNF-α induced expression of
several other ECAMs as well [6,21,30,32,38,41,57], and
decreased the adhesion of α4β7-expressing lymphocytes
(TK-1) to TNF-α stimulated endothelium. Since at least
50% of the adhesion of these lymphocytes to TNF-stimu-
lated endothelium is MAdCAM-1-dependent [35], our
results suggest that MAdCAM-1 mediates most of the
stimulated adhesion, with more minor contributions
from other ECAMs. The results strongly support a novel
therapeutic action of PPAR-γ activators like troglitazone
which might explain their beneficial effects PPAR-γ ago-
nists in murine models of colitis [12,51] and in human
ulcerative colitis [27].
TNF-α induced E-selectin protein expression is reduced by troglitazone, a PPAR-γ ligand Figure 5
TNF-α induced E-selectin protein expression is reduced by troglitazone, a PPAR-γ ligand. TNF-α (1 ng/ml, 24 h) 
induced E-selectin expression was blocked by the PPAR-γ ligand, troglitazone at 20 µM (Fig. 5). Alone, this compound had no 
effect on the expression of E-selectin (Fig. 5).
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NF-kB is a member of the Rel family of dimeric transcrip-
tion factor complexes key transcription factor that modu-
lates expression of MAdCAM-1 in inflammation, and is
governs the expression of several other endothelial adhe-
sion molecules in response to cytokines
[9,22,33,35,40,52]. Prior to cytokine stimulation, NF-kB
is restricted to the cytosol as an inactive complex with its
inhibitor, Ik-B. Upon activation by cytokines, Ik-B is phos-
phorylated, dissociates from the NF-kB, and is subse-
quently ubiquitinated and degraded. This allows active
NF-kB to enter the nucleus and bind kB consensus regula-
tory elements in the promoters of the genes for several
ECAM (ICAM-1, VCAM-1, E-selectin, and MAdCAM-1)
[9,33-36,54]. NF-kB can be activated through several
kinases including IkB kinases (IKKs). IKKs phosphorylate
IkB, but also phosphorylate the p65 NF-kB subunit on
Serine-536 as part of the activation of the NF-kB complex.
Phosphorylation of the p65 subunit is an important step
in the activation of the NF-kB complex which permits this
complex to enter the nucleus and activate NF-kB depend-
ent genes [45]. Consequently, phosphorylation of p65
has been proposed as a simple index of NF-kB activation
[45], although it may not be as sensitive as the electro-
phoretic mobility shift assay (EMSA).
PPAR-γ ligands like troglitazone apparently suppress acti-
vation of NF-kB, and in our hands reduce both basal and
TNF-stimulated NF-kB p65 phosphorylation (figure 7).
Consequently, glitazones like troglitazone should reduce
the expression of both cytokines and ECAMs driven by
Adhesion of α4β7 expressing lymphocytes (TK-1) to TNF-α stimulated endothelium Figure 6
Adhesion of α4β7 expressing lymphocytes (TK-1) to TNF-α stimulated endothelium. TNF-α stimulation (24 h) sig-
nificantly increased adhesion of TK-1 lymphocytes to monolayers of SVEC cells. Troglitazone (20 µM) significantly reduced TK-
1 adhesion in response to TNF-α stimulation at 24 h (Fig. 6).
50
60
70
80
90
100
Control
Troglitazone
TNF
TNF + Troglitazone
T
K
-
1
 
A
d
h
e
s
i
o
n
%
 
T
N
F
-
 
s
t
i
m
u
l
a
t
e
dBMC Physiology 2005, 5:3 http://www.biomedcentral.com/1472-6793/5/3
Page 8 of 12
(page number not for citation purposes)
NF-kB [6,41,57]. Interestingly, under control culture con-
ditions, we observe basal phosphorylation of p65, sug-
gesting that normally, p65 is at least partially activated.
This may be related to the role of basal NF-kB activity in
maintaining cell survival and blocking apoptosis [8,42].
Since excessive inhibition of NF-kB can propel cells into
apoptosis, agents like troglitazone, (which may inhibit
NF-kB) could have a limited therapeutic window, and
should be administered cautiously. However, under the
conditions used in our study, (10–40 µM) we did not see
evidence for the loss of cell viability assessed by trypan
blue staining; all cells remained >99% viable by this
method. In addition, the concentration of troglitazone in
our study (10–40 µM) is near the therapeutic level since
the physiological levels of glitazones, like troglitazone are
5–20 µM, with an average dose of 15 µM [28].
PPAR-γ ligands like glitazones should not only attenuate
MAdCAM-1, but also diminish the expression of other
ECAMs like ICAM-1, VCAM-1 and E-selectin. This reflects
a decrease in the synthesis of some, but not all proteins,
since densitometry of troglitazone treated monolayers
shows no difference in total protein content between
wells following troglitazone, but western blotting or
surface expression assay find a significant decrease in the
expression of ECAMs.
TNF-α induced phosphorylation of NF-kB p65 is prevented by troglitazone, a PPAR-γ ligand Figure 7
TNF-α induced phosphorylation of NF-kB p65 is prevented by troglitazone, a PPAR-γ ligand. TNF-α (1 ng/ml, 1 h) 
induced phosphorylation of NF-kB p65 was significantly attenuated by the PPAR-γ ligand, troglitazone (20 µM). Alone, troglita-
zone also attenuated phosphorylation of NF-kB p65.
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While studies with glitazones in endothelial models for
the most part demonstrate an inhibition of ECAMs such as
ICAM-1 in response to TNF-α [10,38], Chen et al. [6,7]
have reported that the ECV304 cell line showed an
increase in the expression of ICAM-1 in response to trogl-
itazone. This stands in sharp contrast to our current study.
However, since The ECV304 cell line has been mistakenly
designated as 'endothelial' in many cases, (and is actually a
bladder carcinoma in many instances) [56], those results
may be called into question.
It is also possible that PPAR-γ activators might well affect
inflammation through NF-kB independent  pathways.
Some described PPAR-γ ligands, like the cyclopentanone
prostanoids, exert anti-inflammatory effects through a
PPAR-γ-independent pathways [43] specifically the inhi-
bition of the IKK beta subunit which would suppress NF-
kB activation. Further, troglitazone also activates ERK1/2
[20] and blocks c-fos synthesis [6] which could also mod-
ulate these effects. Therefore, we cannot completely
exclude the possibility that troglitazone similarly protects
in these models through direct inhibition of IKK, as well
as indirect blockade through PPAR-γ.
Since high levels of PPAR-γ protein are expressed within
the colon, [13] it is possible that agonists for this pathway
could have an important role in the regulation of normal
colon functioning and disease progress.
Conclusions
Our results indicate that troglitazone and other glitazones
may provide an effective means of treating forms of
chronic inflammation including inflammatory bowel dis-
ease through their ability to interfere with steps in the acti-
vation of NF-kB, effectively blocking the expression of
adhesion molecules like MAdCAM-1 which increase infil-
tration of tissues by leukocytes.
Methods
Reagents
Recombinant mouse TNF-α was purchased from
ENDOGEN (Stoughton, MA), and troglitazone was pro-
vided as a generous donation from Sankyo corp., Japan.
Cell culture
The SVEC4-10 line is an endothelial cell line derived by
SV40 (strain 4A) transformation of murine small vessel
endothelial cells, originally isolated from the axillary
lymph node vessels of an adult male C3H/Hej mouse
[4,5]. These cell types were all maintained in Dulbecco's
modified Eagle's medium (DMEM) with 10% fetal calf
serum with 1% antibiotic/ antimycotic. Cells were seeded
into 24-well tissue culture plates at approximately 20,000
cells/cm2, and cultures were used immediately upon
reaching confluence (usually 3–4 days after seeding).
Lymphocytes
The mouse CD8+ T cell lymphoma TK-1 cells (that consti-
tutively expresses the α4β7 integrin [44] were obtained as
a generous gift from Dr. Eugene Butcher (Stanford Univer-
sity, CA). These cells were cultured in RPMI-1640 medium
supplemented with 10% FCS and 0.05 mM 2-mercap-
toethanol (minus antibiotic/ antimycotic).
PPAR-γ expression on SVEC endothelial cell – Western 
analysis of cell lysates
Cell lysates were electrophoretically separated on 7.5%
SDS- PAGE gels, transferred to nitrocellulose, blocked and
incubated in primary anti-PPAR-γ synthetic peptide
(Affinity Bioreagents Inc., Golden, CO) at a 1: 500 dilu-
tion overnight (4°C). Membranes were washed 2× with
wash buffer. Secondary goat anti-rabbit horseradish per-
oxidase conjugated secondary antibody (Sigma) was
added at a 1:2,000 dilution for 1 h. Membranes were
washed 3 times and developed using the ECL detection
system (Amersham, La Jolla, CA).
Western analysis of cell lysates
Monolayers were either pretreated (1 h) with blockers,
and then incubated with cytokines (24 h), or treated with-
out test agents and then treated with cytokines (24 h). All
cell samples were harvested at 24 hours. Equal quantities
of protein (75 µg) from each sample were electrophoreti-
cally separated on 7.5% SDS- PAGE gels. Gels were trans-
ferred to nitrocellulose membranes (Sigma) and blocked
with 5% milk powder in PBS at 4°C (overnight). These
membranes were washed twice for 10 min with wash
buffer (0.1% milk powder in PBS). Primary rat anti-
mouse MAdCAM-1 mAb (MECA 367; generous gift from
Dr. Sharon Evans, RPMI, NY) was added at a concentra-
tion of 10 µg/ml and incubated at room temperature for 2
h. In p65 NF-kB phosphorylation studies, membranes
were incubated with anti-phospho p65 antibody (Cell
Signaling Technology, Beverly, MA) diluted 1:1000 over-
night (4°C). These membranes were washed twice with
wash buffer. Secondary goat anti-rat horseradish peroxi-
dase conjugated secondary antibody (Sigma) was added
at a 1:2000 dilution for 2 h for MAdCAM-1, while goat
anti-rabbit antibody was used for detecting phospho-p65
NF-kB. Lastly, membranes were washed 3 times and
developed using the enhanced chemiluminescence (ECL)
detection system. The density of MAdCAM-1 staining was
measured by scanning the 60 KD band, using a HP Scan-
Jet™ flatbed scanner. Images were analyzed for density
using Image Pro Plus™ image analysis software (Media
Cybernetics, Silver Springs, MD). The data are expressed
as a percentage of TNF-α-induced level of density.BMC Physiology 2005, 5:3 http://www.biomedcentral.com/1472-6793/5/3
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Endothelial cell surface adhesion molecule expression 
assay
Surface expressions of ECAMs were measured using the
method of Khan et al. [26]. SVEC monolayers were grown
in 48-well plates as described and were pretreated (1 h)
with troglitazone and of 1 µg/ml in HBSS/PBS + 5% FCS
at 37°C for 30 min. Monolayers were then washed twice
with 0.5 ml HBSS/PBS, and incubated with horseradish
peroxidase conjugated rabbit anti-rat IgG (1:2,000
diluted, Sigma) in HBSS/PBS + 5% FCS at 37°C for 30
min. Monolayers we then co-treated with TNF-α (1 ng/
ml) at 37°C in medium for 24 h. The cells were washed
three times with 0.5 ml HBSS/PBS [1:1] at 24 hours, and
monolayers incubated with anti-mouse VCAM-1, anti-
ICAM-1 or anti-E-selectin. All antibodies were added to
cultures after treatment at a concentration re washed four
times with 0.5 ml HBSS/PBS followed by incubation with
0.25 ml of 0.003% hydrogen peroxide + 0.1 mg/ml 3, 3',
5, 5'-tetramethlbenzidine (Sigma) at 37°C for 60 min in
the dark. The color reaction was stopped by adding 75 µl
of 8 N H2SO4, and the samples were transferred to 96-well
plates. Plates were read on a Titertek MCC340 plate reader
(Titertek Instruments, Inc., Huntsville, AL) at 450 nm.
Blanking (i.e. background) was performed on monolayers
stained only with second antibody and reacted as above.
TK-1 lymphocyte adhesion assay
Briefly, TK-1 cells were suspended in culture medium and
fluorescence labeled by incubating TK-1 cells at 2 × 106
cells/ml with 0.02 mg fluorescein diacetate (FDA)
(Sigma) at 37°C for 30 min. The cells were then washed
twice with ice-cold HBSS, spun at 250 g for 5 min to
remove unincorporated fluorescence and suspended in
HBSS. The TK-1 lymphocyte cell line used in this assay
expresses high levels of the α4β7 integrin, [35,44] which
can interact with multiple ligands including mucosal
addressin-1 (MAdCAM-1), as well as VCAM-1, L-selectin
and fibronectin [18]. In this system, TNF stimulated TK-1
adhesion to SVEC4-10 endothelial cells is at least 50%
MAdCAM-1 dependent [35]. SVEC monolayers were
grown in 48-well plates as described, and to activate
endothelium, the monolayers were incubated with TNF-α
(1 ng/ml) for 24 h. Cytokine treated endothelial cells were
washed three times with media. Labeled TK-1 cells were
then added to the endothelium at a 5:1 lymphocyte to
endothelial cell ratio [31] and allowed to bind for 30 min
under static conditions. At the end of the incubation
period, the supernatant was removed and the Monolayers
were washed twice with HBSS. Plates were read on a
Fluorescent Ascent (Lab systems, Helsinki, Finland) set for
excitation at 485 nm, and emission at 515 nm. Blank
wells (0% TK-1 adhesion) were run as controls that did
not contain labeled TK-1 cells; 100% adhesion was meas-
ured on monolayers where TK-1 cells were not removed
from the supernatant.
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